Straits Times Index
3,325.41 -0.87 (-0.03%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,093.37 +20.47 (+0.11%) FTSE 100
8,299.61 +51.82 (+0.63%) Bitcoin USD
61,461.91 +620.35 (+1.02%) CMC Crypto 200
1,280.51 -3.27 (-0.25%)
HALO Dec 2024 45.000 call
| Previous close | 10.31 |
| Open | 10.16 |
| Bid | 9.40 |
| Ask | 11.50 |
| Strike | 45.00 |
| Expiry date | 2024-12-20 |
| Day's range | 10.16 - 10.31 |
| Contract range | N/A |
| Volume | |
| Open interest | 699 |
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- PR Newswire
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
